This article is more than 5 years old. Information may no longer be current.
Vision aids, environmental adaptation can improve visual function and independence of glaucoma patients
Click Here to Manage Email Alerts
 Eydie G. Miller-Ellis |
MILAN, Italy — The job of glaucoma specialists does not end with IOP control. When vision starts to be affected, patients may need low vision services, occupational therapy, counseling and group support to adjust to disability, according to a speaker here.
“Vision loss causes loss of independence and self-esteem. Rehabilitation teaches patients how to maximize residual vision and increase functionality within their environment,” Eydie G. Miller-Ellis, MD, said at the annual joint meeting of OSN and the Italian Society of Ophthalmology.
It is necessary to talk to patients, assess the impact of vision loss on their life, identify problem areas and facilitate appropriate referral.
The first goal is to optimize visual function with devices and environmental enhancements. Low vision aids, such as magnifying glasses or high add clip-ons, may be useful for reading and shopping, and special lenses that decrease glare and improve contrast can be used for driving.
“Adequate illumination, with architect lamps or magnifying lamps, can tremendously help reading. Patients should also be advised to place their lamp close to the reading material and not over their shoulders. Tabletop or portable [closed circuit] TV systems are nowadays available,” Dr. Miller-Ellis said.
For distance vision tasks, telescopic lenses combined with mobility training can help patients to regain independence outside the home.
“Inside the home, a high-contrast living space should be organized, like dark furniture against white walls and varying the color of plates and bowls based on the color of food,” Dr. Miller-Ellis said.
In addition, talking watches and large-print versions of household items such as telephones and remote controls can be used.
- Disclosure: Dr. Miller-Ellis is on the speakers bureaus for Alcon, Allergan and Merck.